= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. AMENDED AND RESTATED ANTIBODY DISCOVERY AND...Antibody Discovery and Option Agreement • June 18th, 2024 • ARCA Biopharma, Inc. • In vitro & in vivo diagnostic substances • Massachusetts
This Amended and Restated Antibody Discovery and Option Agreement (“Agreement”) is entered into and effective as of March 28, 2024 (the “New Effective Date”), by and among Paragon Therapeutics, Inc., a Delaware corporation (“Paragon”), Paruka Holding, LLC, a Delaware limited liability company (“Paruka”) and Oruka Therapeutics, Inc., a Delaware corporation (“Oruka”). Paragon, Paruka and Oruka are also referred to herein individually as a “Party”, or collectively as the “Parties.”
= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. AMENDED AND RESTATED ANTIBODY DISCOVERY AND...Antibody Discovery and Option Agreement • June 18th, 2024 • ARCA Biopharma, Inc. • In vitro & in vivo diagnostic substances • Massachusetts
This Amended and Restated Antibody Discovery and Option Agreement (“Agreement”) is entered into and effective as of March 28, 2024 (the “New Effective Date”), by and among Paragon Therapeutics, Inc., a Delaware corporation (“Paragon”), Paruka Holding, LLC, a Delaware limited liability company (“Paruka”) and Oruka Therapeutics, Inc., a Delaware corporation (“Oruka”). Paragon, Paruka and Oruka are also referred to herein individually as a “Party”, or collectively as the “Parties.”
